Express News | Fuan Pharmaceutical: The subsidiary Qingyutang recently received a drug registration certificate issued by the State Drug Administration
Fu'an Pharmaceutical (300194.SZ): Qingyutang received drug registration certificates for pentazocin injections and midazolam injections
On April 30, Gelonghui Pharmaceutical (300194.SZ) announced that Fu'an Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. (“Qingyutang”), a wholly-owned subsidiary of the company, recently received a drug registration certificate issued by the State Drug Administration. The related drugs are pentazocin injection and midazolam injection, respectively. Pentazocine injection is suitable for all kinds of severe chronic pain, such as cancerous pain, traumatic pain, and pain after surgery. It can also be used for administration before surgery or before anesthesia, as an adjuvant to surgical anesthesia. Up to now, 2 companies (including Qingyutang) have passed the consistency evaluation or been deemed to have passed the drug
Fuan Pharmaceutical (300194.SZ) announced its 2023 annual results, with net profit of 232 million yuan, an increase of 13.32%
Fuan Pharmaceutical (300194.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 2...
Fuan Pharmaceutical (300194.SZ): Midazolam hydrochloride obtained approval notice for the marketing application of chemical raw materials
Fuan Pharmaceutical (300194.SZ) announced that Fuan Pharmaceutical Group Chongqing Bosheng Pharmaceutical Co., Ltd. (“Bosheng Pharmaceutical”), a wholly-owned subsidiary of the company, recently received a chemical ingredient marketing application approval notice issued by the State Drug Administration. The name of the ingredient is midazolam hydrochloride, which is mainly used for pre-anesthetic administration, induction and maintenance of general anesthesia, adjuvant medication, diagnostic or therapeutic procedures during local anesthesia (such as cardiovascular radiography, cardiac arrhythmia, bronchoscopy, gastrointestinal endoscopy, etc.) Sedation, ICU patient sedation.
Fuan Pharm Unit's Hemorrhage Drug Gets Registration Certificate From China's Drug Regulator
Fuan Pharm (SHE:300194) said China's National Medical Products Administration (NMPA) issued a drug registration certificate for Nimodipine Tablets, according to a Monday filing on the Shenzhen Stock E
Fuan Pharmaceutical (300194.SZ): Nimergoline tablets received a drug registration certificate
Gelonghui, April 7 | Fu'an Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary Fu'an Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. recently received a drug registration certificate issued by the State Drug Administration. Drug name: nimegoline tablets. Nimergoline tablets are suitable for improving low motivation due to the sequelae of a stroke; they are also suitable for vascular dementia. In particular, during early treatment, they improve cognition, memory, etc., and can reduce the severity of the disease.
Fuan Pharmaceutical (300194.SZ): Does not produce radiation protection drugs
Gelonghui, March 28 | Fuan Pharmaceutical (300194.SZ) said on the investor interactive platform that the company currently does not produce radiation-proof drugs, and that the company will keep an eye on diseases and radiation lesions that may be caused to humans by draining nuclear sewage into the sea.
Express News | Fuan Pharmaceutical said on an interactive platform on March 11 that the company currently does not produce diet drugs.
Fuan Pharmaceutical (300194.SZ): Currently not producing diet drugs
Gelonghui March 11 丨 An investor asked Fuan Pharmaceutical (300194.SZ) on the investor interactive platform, “How is the negotiation process for the company to introduce the production of diet pills to Lilai?” The company replied that the company currently does not produce diet drugs.
Fuan Pharmaceutical (300194.SZ): As of February 29, 2024, the number of shareholders of the company was 42,888
Gelonghui March 6 | Fuan Pharmaceutical (300194.SZ) said on the investor interactive platform that as of February 29, 2024, the number of shareholders of the company was 42,888.
Drugs of Fuan Pharma's Unit Passes Regulatory Evaluation
Fuan Pharmaceutical Group's (SHE:300194) subsidiary, Qingyutang Pharmaceutical, received the approval of China's National Medical Products Administration on a supplementary application for cefoperazon
Fuan Pharmaceutical (300194.SZ): Injectable cefoperazone sodium and sulbactam sodium passed the consistent evaluation of generic drug quality and efficacy
On February 21, Gelonghui Pharmaceutical (300194.SZ) announced that Fu'an Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. (hereinafter referred to as “Qingyutang”), a wholly-owned subsidiary of the company, recently received a drug supplement application approval notice issued by the State Drug Administration. After review, injectable cefoperazone sodium and sulbactam sodium passed the consistent evaluation of generic drug quality and efficacy. Injectable cefoperazone sodium and sulbactam sodium is mainly suitable for treating various types of upper and lower respiratory infections, urinary tract infections, sepsis, peritonitis, skin and soft tissue infections, bone and joint infections, pelvic inflammation, endometritis, etc. caused by sensitive bacteria
Express News | Fuan Pharmaceutical: The subsidiary received a notice of approval for the marketing application of voriconazole as a chemical raw material
Fuan Pharmaceutical (300194.SZ) issued an advance increase. Net profit for 2023 is expected to be 240 million yuan to 290 million yuan, an increase of 17.3% to 41.73% over the previous year
Fuan Pharmaceutical (300194.SZ) disclosed its 2023 annual results forecast. The company is expected to be a shareholder of a listed company...
Fuan Pharmaceutical (300194.SZ): There are currently no paclitaxel-related drugs
Gelonghui January 30 丨 Fuan Pharmaceutical (300194.SZ) said on the investor interactive platform that the company currently has no paclitaxel-related drugs.
Express News | Fuan Pharmaceutical: The subsidiary received a drug registration certificate for lecadipine hydrochloride tablets
Fuan Pharmaceutical (300194.SZ): Injectable hydrocortisone sodium succinate passed the consistent evaluation of generic drug quality and efficacy
On January 25, Gelonghui Pharmaceutical (300194.SZ) announced that Fuan Pharmaceutical Group Hubei People's Pharmaceutical Co., Ltd. (“People's Pharmaceutical”), a wholly-owned subsidiary of the company, recently received a notice of approval for the drug supplement application for injectable hydrocortisone sodium succinate issued by the State Drug Administration. After review, the product passed the consistent evaluation of generic drug quality and efficacy. Injectable hydrocortisone sodium succinate is mainly used to rescue critical patients such as toxic infections, anaphylactic shock, severe hypoadrenocorticism, connective tissue disease, severe bronchial asthma, etc., and can also be used to prevent and
Fuan Pharmaceutical (300194.SZ): As of January 19, 2024, the number of shareholders of the company was 42,662
Gelonghui January 24 | Fuan Pharmaceutical (300194.SZ) said on the investor interactive platform that as of January 19, 2024, the number of shareholders of the company was 42,662.
Fuan Pharmaceutical (300194.SZ): Application for marketing of chemical raw material paramivir approved
Fuan Pharmaceutical (300194.SZ) issued an announcement. Fuan Pharmaceutical Group Ningbo Tianheng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company...
Express News | Fuan Pharmaceutical: The subsidiary received a notice of approval for the drug supplement application
No Data